M&A / Deals Merck’s deal for Terns sparks debate over a possible biotech bidding war BioPharma DiveSome investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run.M&A / DealsRead full story pharminent March 26, 2026 (Last updated: March 27, 2026) BioPharma Dive Some investors and analysts believe the pharma s $6.7 billion offer is justified given Terns recent stock run. M&A / DealsRead full story Post navigation Previous: FDA clears Denali drug in ‘clear step’ for rare disease biotechsNext: The Rare Journey Needs a Special Pharmacy Partner Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
